Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
14:30
TUAB0101
Efficacy and safety of switching from boosted-protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
Jean-Michel Molina, University of Paris Diderot, France
Abstract
Slides
14:45
TUAB0102
Switching from a boosted protease inhibitor (PI/r) based regimen to a dolutegravir regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years is non-inferior and decreases lipids
Jose M Gatell, University of Barcelona, Spain
Abstract
Slides
15:00
TUAB0103
Efficacy of dual therapy with protease inhibitors plus lamivudine as maintenance treatment in HIV-positive patients on second-line in Africa: the ANRS 12286/MOBIDIP trial 96 weeks results
Laura Ciaffi, Université de Montpellier, Cameroon
Abstract
Slides
15:15
TUAB0104LB
Fixed dose combination of doravirine/lamivudine/TDF is non-inferior to efavirenz/emtricitabine/TDF in treatment-naïve adults with HIV-1 infection: week 48 results of the Phase 3 DRIVE-AHEAD study
Kathleen E. Squires, Thomas Jefferson University Hospital, United States
Abstract
Slides
15:30
TUAB0105LB
Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study
Michael Aboud, ViiV Healthcare, United Kingdom
Abstract
Slides
15:45
TUAB0106LB
HIV-specific broadly-neutralizing monoclonal antibody, VRC01, minimally impacts time to viral rebound following treatment interruption in virologically-suppressed, HIV-infected participants who initiated antiretroviral therapy during acute HIV infection
Trevor A. Crowell, U.S. Military HIV Research Program, United States
Abstract
Slides